STANTON L GERSON
Medical Practice in Cleveland, OH

5733542, Mar 31, 1998

Jan 24, 1995

8/377771

Stephen E. Haynesworth - Cleveland Heights OH
Arnold I. Caplan - Cleveland Heights OH
Stanton L. Gerson - Pepper Pike OH
Hillard M. Lazarus - Shaker Heights OH

A01N 6300, A61F 200, C12N 500

424 937

Method and preparations for enhancing bone marrow engraftment in an individual by administering (i) a culturally expanded mesenchymal stem cell preparation and (ii) a bone marrow graft. The mesenchymal stem cells are administered in an mount effective to promote engraftment of the bone marrow.

6635677, Oct 21, 2003

Feb 19, 2002

10/079049

Stanton L. Gerson - Pepper Pike OH
Lili Liu - Euclid OH

Case Western Reserve University - Cleveland OH

A61K 3113

514645, 514589, 514274, 514262, 514 50, 514 49, 514 34, 514 33, 514 23

This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for the treatment of certain cancers. Specifically, the invention contemplates that temozolomide and methoxyamine, in combination or in sequence, shall be used as a treatment for certain tumors that are resistant to treatment by temozolomide alone. Additionally, methoxyamine is contemplated for methods of treatment of cancer, wherein methoxyamine is used, in combination or in sequence, with other anticancer drugs or agents.

6465448, Oct 15, 2002

Aug 13, 1999

09/373693

Stanton L. Gerson - Pepper Pike OH
Lili Liu - Euclid OH

Case Western Reserve University - Cleveland OH

A61K 3133

514183, 514645

This invention generally relates to novel compositions and methods for the treatment of certain cancers. Additionally, this invention relates to novel compositions and methods to screen drugs for the treatment of certain cancers. Specifically, the invention contemplates that temozolomide and methoxyamine, in combination or in sequence, shall be used as a treatment for certain tumors that are resistant to treatment by temozolomide alone.

5300422, Apr 5, 1994

Dec 4, 1991

7/802162

Stanton L. Gerson - Pepper Pike OH
Herbert Meltzer - Shaker Heights OH

Case Western Reserve University - Cleveland OH

C12Q 100, G01N 3348

435 4

A screening method for detecting the vulnerability of patients on clozapine therapy to developing agranulocytosis which comprises establishing the concentration of N-desmethylclozapine in the blood or bone marrow of said patient. In addition, a method of determining patient sensitivity to N-desmethylclozapine is provided which comprises collecting heparinized blood and assaying it for stem cell sensitivity to N-desmethylclozapine.

5591625, Jan 7, 1997

Nov 24, 1993

8/158000

Stanton L. Gerson - Pepper Pike OH
Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH

Case Western Reserve University - Cleveland OH

C12N 510, C12N 508, C12N 1586, A61K 4800

4352402

Genetically engineered human stem cells that carry within them genes of interest particularly for the expression of physiologically or pharmacologically active proteins or for use in gene therapy. In addition to correction of genetic disorders, is the ability to introduce, in a targeted manner, additional copies of essential genes to allow expression in proliferating, nondifferentiating cells of certain gene products. These genes can be, for example, hormones matrix proteins, cytokines, adhesion molecules, detoxification enzymes and "rebuilding" proteins important in tissue repair.

6010696, Jan 4, 2000

Mar 25, 1998

9/047950

Arnold I. Caplan - Cleveland Heights OH
Stephen E. Haynesworth - Cleveland Heights OH
Stanton L. Gerson - Pepper Pike OH
Hillard M. Lazarus - Shaker Heights OH

Osiris Therapeutics, Inc. - Baltimore MD

C12N 500, A61K 3528, A61F 1300

424 937

Method and preparations for enhancing hematopoietic progenitor cell engraftment in an individual by administering (i) a culturally expanded mesenchymal stem cell preparation and (ii) hematopoietic progenitor cells. The mesenchymal stem cells are administered in an amount effective to promote engraftment of the hematopoietic progenitor cells.

8318495, Nov 27, 2012

May 28, 1999

09/321655

Stanton L. Gerson - Pepper Pike OH, US

Case Western Reserve University - Cleveland OH

C12N 15/63, C12N 5/00, A61K 48/00

435455, 435373

Genetically engineered hematopoietic progenitor cells that carry within them genes of interest, particularly for the expression of physiologically or pharmacologically active proteins. The hematopoietic progenitor cells are transduced in the presence of human mesenchymal stem cells which enhance transduction efficiency.